Earnings ·
Evaxion A/S filed its unaudited condensed consolidated interim financial results for the six months ended June 30, 2026
EVAXEvaxion A/S
Evaxion A/S filed its unaudited condensed consolidated interim financial results for the six months ended June 30, 2026. The company reported a net loss of $7.4 million, compared to a $6.4 million loss in the prior year period. Research and development expenses increased slightly to $4.6 million from $4.3 million, while general and administrative expenses decreased to $3.0 million from $3.9 million due to lower capital market transaction costs. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, down from $23.2 million at year-end 2025. Management stated that current liquidity is sufficient to fund operations into the second half of 2027. The company operates in the biopharmaceutical industry, developing personalized and off-the-shelf cancer vaccines using its AI-Immunology platform.